Voxilaprevir
Protease inhibitor
Clinical data | |
---|---|
Trade names | Vosevi (combination with sofosbuvir and velpatasvir) |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
PDB ligand |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C40H52F4N6O9S |
Molar mass | 868.94 g·mol−1 |
3D model (JSmol) | |
Density | 1.4±0.1[1] g/cm3 |
| |
InChI
|
Voxilaprevir is a hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease inhibitor (by Gilead) that is used in combination with sofosbuvir and velpatasvir.[2] The combination has the trade name Vosevi and received a positive opinion from the European Committee for Medicinal Products for Human Use in June 2017.[3]
On 18 July 2017, Vosevi was approved by the US Food and Drug Administration.[4]
References
- ^ "voxilaprevir_msds".
- ^ Heo YA, Deeks ED (April 2018). "Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C". Drugs. 78 (5): 577–587. doi:10.1007/s40265-018-0895-5. PMID 29546556. S2CID 4395880.
- ^ "Summary of opinion: Vosevi" (PDF). European Medicines Agency. 22 June 2017.
- ^ FDA approves Vosevi for Hepatitis C
- v
- t
- e
NS3/4A protease inhibitors (–previr) |
|
---|---|
NS5A inhibitors (–asvir) | |
NS5B RNA polymerase inhibitors (–buvir) |
|
Combination drugs |
Interferon | |
---|---|
3CL protease inhibitors (–trelvir) | |
RNA pol inhibitors | |
Multiple/Unknown/Other |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e